{"favorite_id": 2046, "calc_type": "calculator", "dosing": false, "full_title_en": "UCSF-CAPRA Score for Prostate Cancer Risk", "short_title_en": "UCSF-CAPRA Score", "medium_description_en": "Predicts outcomes of patients post-treatment for prostate cancer.", "short_description_en": "Post-treatment outcomes for prostate cancer.", "before_use": "", "instructions_en": "", "purpose_en": ["Prognosis"], "disease_en": ["Cancer"], "specialty_en": ["Hematology and Oncology", "Urology"], "chief_complaint_en": ["Weight Loss/Gain"], "system_en": ["Urinary", "Oncologic"], "search_abbreviation_en": ["prostate CA", "CA"], "slug": "ucsf-capra-score-prostate-cancer-risk", "seo": {"meta_description_en": "The UCSF-CAPRA (Cancer of the Prostate Risk Assessment) Score predicts outcomes of patients post-treatment for prostate cancer.", "keywords_en": "ucsf score prostate, ucsf capra, capra, capra score, capra equation, capra calculator, posttreatment prostate calc, post treatment prostate CA, post treatment prostatectomy, posttreatment outcomes prostate"}, "content": {"how_to_use": {"use_case_en": "", "pearls_pitfalls_en": "<p>A prognostic score for prostate cancer, incorporating both the PSA and <calculator id='2048'>Gleason Score</calculator>, designed to be both simple but with an accuracy comparable with the best nomograms.</p>", "why_use_en": ""}, "next_steps": {"advice_en": "<ul>\n<li>For very <g class=\"gr_ gr_12 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling multiReplace\" id=\"12\" data-gr-id=\"12\">low risk</g> patients, consider routine surveillance.</li>\n<li>For low to intermediate-risk patients, consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy).</li>\n<li>For intermediate to high-risk patients, consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).</li>\n<li>For very high-risk patients (scores &ge;8 points), consider either multimodal therapy OR hormonal therapy, and clinical trial enrollment.</li>\n</ul>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p>Addition of the selected points.</p>", "more_info_en": "<p><strong>Score interpretation:</strong></p> <div class='table-responsive'> <table class='table table-bordered table-hover'> <tbody> <tr> <th></th> <th colspan='2'>Metastasis-free interval <br /> % likelihood (95% CI)</th> <th colspan='2'>Prostate cancer\u2013specific survival <br /> % likelihood (95% CI)</th> <th colspan='2'>Overall survival <br /> % likelihood (95% CI)</th> </tr> <tr> <td><strong>CAPRA Risk Group</strong></td> <td><strong>5-year</strong></td> <td><strong>10-year</strong></td> <td><strong>5-year</strong></td> <td><strong>10-year</strong></td> <td><strong>5-year</strong></td> <td><strong>10-year</strong></td> </tr> <tr> <td>Low Risk Group (0-2 points)</td> <td>99.3 (98.8 to 99.5)</td> <td>97.5 (95.9 to 98.5)</td> <td>99.7 (99.9 to 99.5)</td> <td>97.1 (98.2 to 95.1)</td> <td>92.5 (91.5 to 93.5)</td> <td>71.4 (67.8 to 74.7)</td> </tr> <tr> <td>Intermediate Risk Group (3-5 points)</td> <td>96.9 (96.2 to 97.5)</td> <td>93.3 (91.7 to 94.6)</td> <td>98.6 (99.0 to 98.1)</td> <td>91.6 (93.4 to 89.5)</td> <td>90.2 (89.0 to 91.3)</td> <td>59.7 (56.7 to 62.7)</td> </tr> <tr> <td>High Risk Group (\u22656 points)</td> <td>90.4 (88.4 to 92.0)</td> <td>83.4 (79.6 to 86.6)</td> <td>93.4 (94.9 to 91.5)</td> <td>79.1 (83.1 to 74.3)</td> <td>78.7 (75.9 to 81.2)</td> <td>42.0 (37.4 to 46.5)</td> </tr> </tbody> </table> </div> <p>For more detailed risk outcomes, see <a href='http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697208/' target='_blank'>Cooperberg 2009</a>.</p>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697208/", "text": "Cooperberg MR, Broering JM, Carroll PR. Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. JNCI Journal of the National Cancer Institute. 2009;101(12):878-887. doi:10.1093/jnci/djp122."}], "Other References": [{"href": "", "text": ""}], "Validation": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed?term=1837203", "text": "Zhao KH, et al. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology, 2008. 72(2): p. 396-400."}, {"href": "http://www.ncbi.nlm.nih.gov/pubmed?term=17868719", "text": "May M, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients. J Urol, 2007. 178(5): p. 1957-62; discussion 1962."}, {"href": "http://www.ncbi.nlm.nih.gov/pubmed?term=17039503", "text": "Cooperberg MR, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer, 2006. 107(10): p. 2384-91."}, {"href": "http://www.ncbi.nlm.nih.gov/pubmed?term=15879786", "text": "Cooperberg MR, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol, 2005. 173(6): p. 1938-42."}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "creator": [{"name": "Dr. Matthew R. Cooperberg", "creator_info": {"about_en": "<p>Matthew R. Cooperberg, MD, MPH, is an associate professor of urology and epidemiology/biostatistics at UCSF. He practices on the urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center, Mount Zion Medical Center and also operates at San Francisco General Hospital. Dr. Cooperberg researches primarily prostate cancer with a focus on effectiveness of emerging biomarkers on diagnosis and risk assessment, and relative benefits of treatment strategies on cost effectiveness and quality of life.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-matthew-r-cooperberg.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Cooperberg%20MR%5Bauth%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Age", "name": "age", "options": [{"label": "< 50 years", "value": 0}, {"label": "\u2265 50 years", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "radio", "label_en": "PSA at diagnosis (ng/mL)", "name": "psa", "options": [{"label": "<6", "value": 0}, {"label": "\u22656 - 10", "value": 1}, {"label": "\u226510 - 20", "value": 2}, {"label": "\u226520 - 30", "value": 3}, {"label": ">30", "value": 4}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "radio", "label_en": "Gleason Score pattern (primary or secondary)", "name": "gleason", "options": [{"label": "No 4 or 5 pattern present", "value": 0}, {"label": "4 or 5 pattern in secondary", "value": 1}, {"label": "4 or 5 pattern in primary", "value": 3}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "radio", "label_en": "Clinical stage", "name": "stage", "options": [{"label": "T1 or T2", "value": 0}, {"label": "T3a", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "radio", "label_en": "Percent biopsy cores positive for cancer", "name": "biopsy", "options": [{"label": "<34%", "value": 0}, {"label": "\u226534%", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}], "md5": "b44d216ac9c4125e646f2c3ee48f7ffa", "related_calcs": [{"calcId": 2048, "short_title_en": "Gleason Score", "slug": "gleason-score-prostate-cancer"}, {"calcId": 2049, "short_title_en": "D'Amico Classification", "slug": "damico-risk-classification-prostate-cancer"}, {"calcId": 2142, "short_title_en": "Manchester Score for Lung Cancer", "slug": "manchester-score-prognosis-small-cell-lung-cancer"}]}